The History and Development of HER2 Inhibitors-Reference-Cited by-同舟云学术

The History and Development of HER2 Inhibitors

Published:2023-10-12 Issue:10 Volume:16 Page:1450
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Xia Xiaohui¹^ORCID,Gong Chen¹,Zhang Yinan²^ORCID,Xiong Huihua¹

Affiliation:

1. Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

2. School of Chemical Science and Engineering, Tongji University, Shanghai 200092, China

Abstract

HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://www.mdpi.com/1424-8247/16/10/1450/pdf

Reference136 articles.

1. Small molecules, big impact: 20 years of targeted therapy in oncology;Bedard;Lancet,2020

2. The basic biology of HER2;Rubin;Ann. Oncol.,2001

3. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab;Cho;Nature,2003

4. Untangling the ErbB signalling network;Yarden;Nat. Rev. Mol. Cell Biol.,2001

5. Detailed curriculum vitae of HER2-targeted therapy;Zhang;Pharmacol. Ther.,2023

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing;Communications Biology;2024-08-13

2. Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer;Oncogenesis;2024-08-04

3. HER2-targeted therapies beyond breast cancer — an update;Nature Reviews Clinical Oncology;2024-07-22

4. Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study;Oncology and Therapy;2024-07-07

5. Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?;International Journal of Drug Discovery and Pharmacology;2024-05-23